The US Food and Drug Administration (FDA) has granted clearance to Biomea Fusion’s investigational new drug (IND) application, enabling the initiation of the Phase II COVALENT-112 clinical trial of BMF-219 for the treatment of type 1 diabetes (T1D).

The aim of the placebo-controlled, multi-site, double-blind, randomised study is to assess the durability, efficacy, tolerability and safety of the covalent menin inhibitor BMF-219 in restoring beta cell function.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It will compare BMF-219 100 mg and 200 mg doses against placebo control.

Nearly 150 adults with stage 3 type 1 diabetes in an unfed condition will receive these dosages in a 1:1:1 manner for 12 weeks, followed by a 40-week off-treatment period.

Biomea Fusion CEO and Board chairman Thomas Butler said: “We have been diligent to build a programme that will evaluate most people with diabetes, including those with type 1 diabetes.

“I am immensely proud that Team Fusion has achieved these clinical and regulatory milestones more than three months ahead of our guided timelines.

“We have now established a clinical development plan that we believe will fully explore the potential of BMF-219 across the spectrum of diabetes. The next quarters will be very exciting, as we expect these studies will begin to read out.”

BMF-219 has been shown to regenerate and retain insulin-producing beta cells in animal models of type 1 and type 2 diabetes in preclinical studies.

The company is also engaged in developing covalent small molecules to treat patients with genetically defined cancers.